|Company name||CymaBay Therapeutics, Inc.|
NEW YORK, March 3, 2020 –Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CymaBay Therapeutics, Inc. (NASDAQ: CBAY) on behalf of CymaBay stockholders. Our investigation concerns whether CymaBay has violated the federal securities laws and/or engaged in other unlawful business practices.
On January 29, 2020, CymaBay announced in a letter from its President and CEO, that it had been “working to assess all potential ways to maximize value for our shareholders, including liquidation, sale, merger, asset acquisitions, and/or continuing development of our internal programs.”
On this news, CymaBay stock dropped $0.21 per share, or over 11%, to close at $1.65 on January 30, 2020.
If you purchased or otherwise acquired CymaBay shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato or Marion Passmore or by email at email@example.com, telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.